University of Virginia opens center for ablation research
The University of Virginia has opened a state-of-the-art MR-guided focused ultrasound ablation research institute.
The University of Virginia has opened a state-of-the-art MR-guided focused ultrasound ablation research institute. It is designed to become a leading center for translational research and patient care in this new and rapidly evolving field, said provost Dr. Tim Garson on dedication day, Sept 14.
The UVA center will offer uterine fibroid therapy, the first application of the focused ultrasound technology to receive FDA approval. It will also host clinical trials on uterine fibroids and fertility; Parkinson’s disease and epilepsy; liver, brain, breast, and prostate tumors; and pain control from bone tumors. The state of Virginia and the Focused Ultrasound Surgery Foundation covered $7.1 million of the $8 million cost of establishing the institute. Other contributors included GE Healthcare and InSightec, developer of the first FDA-approved MR-guided focused ultrasound ablation system.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
